Literature DB >> 6382570

5-Aminosalicylic acid enemas in patients with active ulcerative colitis. Influence of acidity on the kinetic pattern.

S Bondesen, O H Nielsen, O Jacobsen, S N Rasmussen, S H Hansen, S Halskov, V Binder, E F Hvidberg.   

Abstract

Enemas containing 1000 mg 5-ASA were administered to patients with active distal colitis in three separate studies: as a single dose in a neutral solution (pH 7.4); as a single dose in a slightly acidic, buffered suspension (pH 4.8); and as multiple doses once a day for 10 days with the acidic enema. 5-ASA was relatively rapidly absorbed from the neutral solution, resulting in plasma concentrations of 5-ASA sometimes two to three times higher than those found after peroral salazosulphapyridine (SASP) treatment. In contrast, absorption from the acidic enema was reduced and/or prolonged, giving plasma concentrations similar to those found during oral SASP treatment. After repeated doses of the acidic enema, plasma concentrations after an enema resembled those seen after the single dose. Urinary excretion was significantly lower, suggesting a reduced fraction of absorption at steady-state conditions. No side effects were observed, and no local irritation was reported. An acidic buffer suspension with 5-ASA seems to be safe for use as enema and deserves further clinical testing for treatment of distal ulcerative colitis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6382570

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  14 in total

Review 1.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

2.  Double-blind, placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using 99mTc-labeled 5-ASA suppositories.

Authors:  C N Williams; G Haber; J A Aquino
Journal:  Dig Dis Sci       Date:  1987-12       Impact factor: 3.199

Review 3.  Pharmacology and pharmacokinetics of 5-aminosalicylic acid.

Authors:  U Klotz; K E Maier
Journal:  Dig Dis Sci       Date:  1987-12       Impact factor: 3.199

4.  Proctocolitis unresponsive to conventional therapy. Response to 5-aminosalicylic acid enemas.

Authors:  M S McPhee; J T Swan; W L Biddle; N J Greenberger
Journal:  Dig Dis Sci       Date:  1987-12       Impact factor: 3.199

5.  Absorption of 5-aminosalicylic acid from colon and rectum.

Authors:  S Bondesen; J B Schou; V Pedersen; Z Rafiolsadat; S H Hansen; E F Hvidberg
Journal:  Br J Clin Pharmacol       Date:  1988-02       Impact factor: 4.335

Review 6.  Clinical pharmacokinetics of slow release mesalazine.

Authors:  M De Vos
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

7.  Quantitative distribution of radiolabeled 5-aminosalicylic acid enemas in patients with left-sided ulcerative colitis.

Authors:  R A Vitti; F Meyers; L C Knight; J A Siegel; L S Malmud; R S Fisher
Journal:  Dig Dis Sci       Date:  1989-11       Impact factor: 3.199

Review 8.  Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

9.  Topical 5-aminosalicylic acid versus prednisolone in ulcerative proctosigmoiditis. A randomized, double-blind multicenter trial. Danish 5-ASA Group.

Authors: 
Journal:  Dig Dis Sci       Date:  1987-06       Impact factor: 3.199

10.  4-Aminosalicylic acid retention enemas in treatment of distal colitis.

Authors:  J Gandolfo; M Farthing; G Powers; K Eagen; M Goldberg; P Berman; M Kaplan
Journal:  Dig Dis Sci       Date:  1987-07       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.